BCM
AZN icon

Bayesian Capital Management’s AstraZeneca AZN Stock Holding History

Bayesian Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,565
Closed -$240K – 155
2025
Q3 		$240K Buy
+1,565
New +$237K 0.05% 426
2025
Q1 		– Sell
-16,050
Closed -$2.1M – 612
2024
Q4 		$2.1M Buy
+16,050
New +$2.25M 0.26% 115
2024
Q3 		– Sell
-13,450
Closed -$2.1M – 685
2024
Q2 		$2.1M Buy
13,450
+11,750
+691% +$1.77M 0.24% 107
2024
Q1 		$230K Sell
1,700
-3,350
-66% -$444K 0.02% 626
2023
Q4 		$680K Sell
5,050
-3,850
-43% -$500K 0.07% 317
2023
Q3 		$1.21M Sell
8,900
-16,250
-65% -$2.22M 0.14% 184
2023
Q2 		$3.6M Buy
25,150
+4,414
+21% +$649K 0.39% 46
2023
Q1 		$2.88M Buy
+20,736
New +$2.79M 0.36% 73
2022
Q2 		– Sell
-15,470
Closed -$2.05M – 785
2022
Q1 		$2.05M Buy
15,470
+8,420
+119% +$1.01M 0.31% 61
2021
Q4 		$821K Sell
7,050
-7,700
-52% -$906K 0.26% 118
2021
Q3 		$1.77M Buy
+14,750
New +$1.72M 0.51% 44
2020
Q3 		– Sell
-8,249
Closed -$873K – 519
2020
Q2 		$873K Buy
8,249
+5,321
+182% +$550K 0.19% 150
2020
Q1 		$262K Sell
2,928
-23,000
-89% -$2.17M 0.06% 506
2019
Q4 		$2.59M Buy
+25,928
New +$2.44M 0.44% 43
2019
Q3 		– Sell
-8,878
Closed -$733K – 514
2019
Q2 		$733K Sell
8,878
-24,600
-73% -$1.93M 0.15% 189
2019
Q1 		$2.71M Buy
33,478
+17,871
+115% +$1.41M 0.52% 43
2018
Q4 		$1.19M Buy
+15,607
New +$1.22M 0.24% 124
2016
Q4 		– Sell
-6,100
Closed -$401K – 597
2016
Q3 		$401K Buy
+6,100
New +$399K 0.26% 137

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bayesian Capital Management's AZN Position: Q4 2025 in Review

Bayesian Capital Management sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 1,565 shares — an estimated $240K sold.

Bayesian Capital Management first reported a position in AZN in Q3 2016 and held it in 18 quarters. The position peaked at $3.6M in Q2 2023. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

  • Bayesian Capital Management reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 1,565 AstraZeneca shares in Q4 2025, an estimated $240K.
  • Bayesian Capital Management first reported a position in AstraZeneca in Q3 2016 and held it in 18 quarters.
  • Bayesian Capital Management's AstraZeneca position peaked at $3.6M in Q2 2023.
  • 1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.